Used in targeted therapy for acute myeloid leukemia (AML), this antibody binds specifically to CD33, a receptor found on the surface of leukemic cells. It enables selective delivery of cytotoxic agents when conjugated to drugs or radioactive isotopes, minimizing damage to healthy cells. Investigated in clinical trials for its role in improving remission rates, especially in older patients unsuitable for intensive chemotherapy. Also serves as a reference in developing new anti-CD33 biosimilars and immunoconjugates.